PMC:6365940 / 1753-2568 JSONTXT

{"project":"2_test","denotations":[{"id":"30735911-20101258-133473699","span":{"begin":219,"end":220},"obj":"20101258"},{"id":"30735911-26742998-133473700","span":{"begin":224,"end":225},"obj":"26742998"},{"id":"30735911-25084222-133473701","span":{"begin":675,"end":676},"obj":"25084222"}],"text":"PDAC is one of the most fatal human malignant cancers, because it is often diagnosed at middle or late stage. It is currently the fourth leading cause of cancer death worldwide with a less than 5% 5-year survival rate [1], [2]. Although some effective treatment measures are used, PDAC death rate is still on the rise. The development of chemoresistance is a major reason leading to chemotherapy failure in pancreatic cancer. Gemcitabine, a deoxycytidine analog that inhibits DNA replication and thereby arrests tumor growth, is widely used single-agent chemotherapy for pancreatic cancer, but high rate of chemoresistance reduce the effectiveness of its clinical treatment [3]. Therefore, it is necessary to find potential adjuvants to reverse the gemcitabine resistance in gemcitabine-resistant pancreatic cancer."}